Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
2014
41
LTM Revenue $60.3M
LTM EBITDA $3.4M
$148M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Journey Medical has a last 12-month revenue of $60.3M and a last 12-month EBITDA of $3.4M.
In the most recent fiscal year, Journey Medical achieved revenue of $56.1M and an EBITDA of -$8.4M.
Journey Medical expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Journey Medical valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $79.2M | $56.1M | XXX | XXX | XXX |
Gross Profit | $42.9M | $52.5M | XXX | XXX | XXX |
Gross Margin | 54% | 94% | XXX | XXX | XXX |
EBITDA | $1.9M | -$8.4M | XXX | XXX | XXX |
EBITDA Margin | 2% | -15% | XXX | XXX | XXX |
Net Profit | -$29.6M | -$3.9M | XXX | XXX | XXX |
Net Margin | -37% | -7% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Journey Medical's stock price is $6.
Journey Medical has current market cap of $143M, and EV of $148M.
See Journey Medical trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$148M | $143M | XXX | XXX | XXX | XXX | $-0.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Journey Medical has market cap of $143M and EV of $148M.
Journey Medical's trades at 2.5x LTM EV/Revenue multiple, and 43.2x LTM EBITDA.
Analysts estimate Journey Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Journey Medical and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $148M | XXX | XXX | XXX |
EV/Revenue | 2.6x | XXX | XXX | XXX |
EV/EBITDA | -17.7x | XXX | XXX | XXX |
P/E | -9.8x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -6.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJourney Medical's NTM/LTM revenue growth is 33%
Journey Medical's revenue per employee for the last fiscal year averaged $1.4M, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Journey Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Journey Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Journey Medical and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -29% | XXX | XXX | XXX | XXX |
EBITDA Margin | -15% | XXX | XXX | XXX | XXX |
EBITDA Growth | -537% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 18% | XXX | XXX | XXX | XXX |
Revenue per Employee | $1.4M | XXX | XXX | XXX | XXX |
Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
Opex to Revenue | 95% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Journey Medical acquired XXX companies to date.
Last acquisition by Journey Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Journey Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Journey Medical founded? | Journey Medical was founded in 2014. |
Where is Journey Medical headquartered? | Journey Medical is headquartered in United States of America. |
How many employees does Journey Medical have? | As of today, Journey Medical has 41 employees. |
Who is the CEO of Journey Medical? | Journey Medical's CEO is Mr. Claude Maraoui. |
Is Journey Medical publicy listed? | Yes, Journey Medical is a public company listed on NAS. |
What is the stock symbol of Journey Medical? | Journey Medical trades under DERM ticker. |
When did Journey Medical go public? | Journey Medical went public in 2021. |
Who are competitors of Journey Medical? | Similar companies to Journey Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Journey Medical? | Journey Medical's current market cap is $143M |
What is the current revenue of Journey Medical? | Journey Medical's last 12-month revenue is $60.3M. |
What is the current EBITDA of Journey Medical? | Journey Medical's last 12-month EBITDA is $3.4M. |
What is the current EV/Revenue multiple of Journey Medical? | Current revenue multiple of Journey Medical is 2.5x. |
What is the current EV/EBITDA multiple of Journey Medical? | Current EBITDA multiple of Journey Medical is 43.2x. |
What is the current revenue growth of Journey Medical? | Journey Medical revenue growth between 2023 and 2024 was -29%. |
Is Journey Medical profitable? | Yes, Journey Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.